2018.Jan.17
FDA Clearance of IND Application for A Phase 1 Study of A Monoclonal Antibody Cancer Immunotherapy (OBI-888)
Date of occurrence of the event: January 17, 2018 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): Head office Reciprocal shareholding ratios: N/A Cause of occurrence: FDA clearance of IND application for a Phase 1 study of a monoclonal antibody cancer immunotherapy (OBI-888) Countermeasures: None Any other […]
This article is password protected.
To view the content, please enter your password in the field below